Finance Watch
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
![](/-/media/editorial/scrip/00_regular-column-images/finance_watch_public_company_2b26bg8_1200_675.jpg?rev=61bfdd40e88a42d9bfad2de44729eba1&w=350&hash=3994E0FA5762024DDC1B3DD1C9F23133)
Finance Watch: Alumis Launches IPO In Market Less Receptive Than Expected
Public Company Edition: Alumis grosses $250m after it planned to raise up to $317.7m in its IPO. Also, Zealand adds $1bn in a post-data offering, Tectonic and Eliem close $130.7m and $120m private placements to support recent mergers, and Ginkgo cuts 35% of its workforce.
![](/-/media/editorial/scrip/00_regular-column-images/finance_watch_private_company_1200_675.jpg?rev=08e535103fc64137a8ebefc93306626d&w=350&hash=9AB8CAA21A02F4913A32E237402983A4)
Finance Watch: More Than $2.5bn In New VC Funding, Capital For Pharma Manufacturing In Africa
Private Company Edition: J.P. Morgan raised more than $500m in its first venture fund and the Africa Health Security Investment Plan gained $2bn. Also, Marea launched with $190m, Iambic’s series B expanded to $150m, InduPro raised an $85m series A and Elion closed an $81m series B.
![](/-/media/editorial/scrip/00_regular-column-images/finance_watch_public_company_2b26bg8_1200_675.jpg?rev=61bfdd40e88a42d9bfad2de44729eba1&w=350&hash=3994E0FA5762024DDC1B3DD1C9F23133)
Finance Watch: SPACs Attempt A Comeback Ahead Of Full IPO Recovery
Public Company Edition: Several special purpose acquisition corporations have emerged, including various health care- and life science-focused SPACs. Also, Alvotech entered into a $965m refinancing agreement and Avidity grossed $461m in a follow-on offering, among other updates.
![](/-/media/editorial/scrip/00_regular-column-images/finance_watch_private_company_1200_675.jpg?rev=08e535103fc64137a8ebefc93306626d&w=350&hash=9AB8CAA21A02F4913A32E237402983A4)
Finance Watch: Lilly’s Gateway Labs, Deerfield’s Cure Offer Biotechs Space To Grow
Private Company Edition: Scrip spoke with the leaders of Gateway Labs and Cure at the BIO International Convention about their mini ecosystems. Also, radiopharmaceutical firm ITM raised €188m ($201.9m), Santa Ana Bio emerged with $168m and Alzheon’s series E totaled $100m.
![](/-/media/editorial/scrip/00_regular-column-images/finance_watch_public_company_2b26bg8_1200_675.jpg?rev=61bfdd40e88a42d9bfad2de44729eba1&w=350&hash=3994E0FA5762024DDC1B3DD1C9F23133)
Finance Watch: Big Money In Post-Data Follow-On Offerings
Public Company Edition: Insmed grossed $650m, Structure raised $476m and Merus brought in $400.2m after positive clinical trial results. But while CARGO raised $110m in a private placement and Day One sold a priority review voucher for $108m, Ikena, Takeda and others cut jobs.
![](/-/media/editorial/scrip/00_regular-column-images/finance_watch_private_company_1200_675.jpg?rev=08e535103fc64137a8ebefc93306626d&w=350&hash=9AB8CAA21A02F4913A32E237402983A4)
Finance Watch: Two New VC Funds Bring $365m For Start-Ups
Private Company Edition: Amplitude Ventures raised $192m for its second fund, while XGEN Venture debuted with €160m ($173.4m). Also, hub-and-spoke biopharma operator CinRx added $73m, Adcendo extended its series A round to €98m ($106.2m) and Grey Wolf raised $50m.
![](/-/media/editorial/scrip/00_regular-column-images/finance_watch_public_company_2b26bg8_1200_675.jpg?rev=61bfdd40e88a42d9bfad2de44729eba1&w=350&hash=3994E0FA5762024DDC1B3DD1C9F23133)
Finance Watch: Cytokinetics Accesses Up To $1bn-Plus, Confirms No-Sale Plan
Public Company Edition: Cytokinetics executed a royalty financing deal for up to $575m and grossed $500m in a follow-on offering. Also, GSK grossed £1.25bn ($1.58bn) in sale of final Haleon shares, Bicycle raised $555m in a private placement and Apellis accessed up to $475m in debt.
![](/-/media/editorial/scrip/00_regular-column-images/finance_watch_private_company_1200_675.jpg?rev=08e535103fc64137a8ebefc93306626d&w=350&hash=9AB8CAA21A02F4913A32E237402983A4)
Finance Watch: AltruBio, Pheon Raise Venture Capital Mega-Rounds
Private Company Edition: AltruBio raised up to $225m and Pheon garnered $120m in series B financings, while Lycia brought in $106.6m in series C cash. Also, Sands Capital closed its third life science fund, totaling $555m, and NewVale Capital debuted with $167m for life science services.
![](/-/media/editorial/scrip/00_regular-column-images/finance_watch_public_company_2b26bg8_1200_675.jpg?rev=61bfdd40e88a42d9bfad2de44729eba1&w=350&hash=3994E0FA5762024DDC1B3DD1C9F23133)
Finance Watch: Verona Accesses Up To $650m As Ensifentrine Approval Deadline Nears
Public Company Edition: Verona Pharma arranged up to $400m in new debt and up to $250m in revenue-related financing ahead of its COPD drug launch. Also, Organon, Sobi and Pacira priced $1bn, $275.1m and $250m note sales, respectively. Marinus, Emergent and Ginkgo cut jobs.
![](/-/media/editorial/scrip/00_regular-column-images/finance_watch_private_company_1200_675.jpg?rev=08e535103fc64137a8ebefc93306626d&w=350&hash=9AB8CAA21A02F4913A32E237402983A4)
Finance Watch: Clinical-Stage Autoimmune Start-Ups Garner Big Investments
Private Company Edition: Attovia will advance two anti-IL-31 programs with its $105m in series B funding, while ImmuNext secured $575m in a Royalty Pharma deal for its Sanofi-partnered drug. Also, Bluejay and Aardvark raised $182m and $85m, respectively, in series C rounds.
![](/-/media/editorial/scrip/00_regular-column-images/finance_watch_private_company_1200_675.jpg?rev=08e535103fc64137a8ebefc93306626d&w=350&hash=9AB8CAA21A02F4913A32E237402983A4)
Finance Watch: Venture Rounds Trend Toward The High End
Private Company Edition: First quarter data again confirm fewer but larger VC rounds in Q1. Big Q2 rounds include a $132.5m series C round for Endeavor Biomedicines, a $103m series A round for Reunion Neuroscience and Enlaza’s $100m series A.
![](/-/media/editorial/scrip/00_regular-column-images/finance_watch_1200_675.jpg?rev=b2e2e86dafac4cb1a7d0fd047655094b&w=350&hash=9B9386B5DAD427BF5DF1DE8491B01AE6)
Finance Watch: Earnings Season Brings Job Cuts, Even At Big Pharma
Restructuring Edition: Even big pharma companies are not immune from workforce reductions. BMS and Sanofi joined that ranks of Evotec, CureVac and BenevolentAI in cutting jobs. Also, Vaxxinity will de-list and Hepion winds down its NASH trial, among other strategic updates.
![](/-/media/editorial/scrip/00_regular-column-images/finance_watch_public_company_2b26bg8_1200_675.jpg?rev=61bfdd40e88a42d9bfad2de44729eba1&w=350&hash=3994E0FA5762024DDC1B3DD1C9F23133)
Finance Watch: Investors Support Strategic Shifts At Cullinan, Cidara
Public Company Edition: Cullinan and Cidara shifted their strategic directions and found investors to bring along for the ride. Also, Intra-Cellular closed a post-Phase III $575m follow-on offering and Tarsus accessed up to $200m from Pharmakon.
![](/-/media/editorial/scrip/00_regular-column-images/finance_watch_private_company_1200_675.jpg?rev=08e535103fc64137a8ebefc93306626d&w=350&hash=9AB8CAA21A02F4913A32E237402983A4)
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
![](/-/media/editorial/scrip/00_regular-column-images/finance_watch_public_company_2b26bg8_1200_675.jpg?rev=61bfdd40e88a42d9bfad2de44729eba1&w=350&hash=3994E0FA5762024DDC1B3DD1C9F23133)
Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar
Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.
![](/-/media/editorial/scrip/00_regular-column-images/finance_watch_private_company_1200_675.jpg?rev=08e535103fc64137a8ebefc93306626d&w=350&hash=9AB8CAA21A02F4913A32E237402983A4)
Finance Watch: Obsidian’s $160.5m Financings Comes In A Flurry Of VC Mega-Rounds
Private Company Edition: Three consecutive $100m-plus venture capital rounds include Obsidian’s series C, a $132m series B round for Alterome and Diagonal’s $128m launch. Also, The Medicines Company’s Clive Meanwell reportedly is heading up a well-founded obesity start-up.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.